HOLX

Hologic Inc

Add to Watchlist

Advanced Chart

74.150

-0.08(-0.108%)1D

Line

Candle

YTD

High

74.240

Open

74.180

VWAP

74.17

Vol

4.16M

Mkt Cap

16.50B

Low

74.110

Amount

308.77M

EV/EBITDA(TTM)

12.86

Total Shares

233.38M

16.83B

EV/OCF(TTM)

15.92

P/S(TTM)

4.11

Hologic, Inc. is a medical technology company primarily focused on improving women's health and well-being through early detection and treatment. The Company is a developer, manufacturer and supplier of diagnostics products, medical imaging systems, and surgical products. Its segments include Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment offers a range of diagnostic products, which are used primarily to aid in the screening and diagnosis of human diseases. The Breast Health segment offers a broad portfolio of solutions for breast imaging, biopsy, breast surgery and pathology. The GYN Surgical segment's products include MyoSure hysteroscopic tissue removal system, NovaSure endometrial ablation system, Acessa ProVu laparoscopic radiofrequency ablation system, as well as CoolSeal vessel sealing portfolio and JustRight surgical stapler. The Skeletal Health segment's products include the Horizon DXA and the Fluoroscan Insight FD mini C-arm.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q3

FY2026Q2

FY2026Q1

1.07B

+4.85%

1.148

+6.29%

1.06B

+5.16%

1.092

+6%

1.08B

+5.8%

1.093

+6.07%

Estimates Revision

The market is revising No Change the revenue expectations for Hologic, Inc. (HOLX) for FY2025, with the revenue forecasts being adjusted by -0% over the past three months. During the same period, the stock price has changed by 10.85%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.05%

In Past 3 Month

Stock Price

Go Up

+10.85%

In Past 3 Month

11 Analyst Rating

Wall Street analysts forecast HOLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HOLX is 80.13 USD with a low forecast of 76.00 USD and a high forecast of 94.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

8 Hold

0 Sell

Moderate Buy

Current: 74.150

Low

76.00

Averages

80.13

High

94.00

Current: 74.150

Low

76.00

Averages

80.13

High

94.00

Mizuho

Outperform -> Neutral

downgrade

$78

2025-10-23

Reason

Mizuho

Price Target

$78

2025-10-23

downgrade

Outperform -> Neutral

Reason

Mizuho downgraded Hologic (HOLX) to Neutral from Outperform with a $78 price target after the company agreed to be acquired by funds managed by Blackstone (BX) and TPG (TPG) in a transaction valued at up to $79 per share, representing an enterprise value of up to $18.3B.

Stephens

Overweight -> Equal Weight

downgrade

$78 -> $76

2025-10-22

Reason

Stephens

Price Target

$78 -> $76

2025-10-22

downgrade

Overweight -> Equal Weight

Reason

Stephens downgraded Hologic (HOLX) to Equal Weight from Overweight with a price target of $76, down from $78, after the company agreed to be acquired by funds managed by Blackstone (BX) and TPG (TPG) in a transaction valued at up to $79 per share. The deal is in line with the firm's expectations and "seems fair based on our outlook," the analyst tells investors.

JPMorgan

Overweight -> Neutral

downgrade

$78

2025-10-21

Reason

JPMorgan

Price Target

$78

2025-10-21

downgrade

Overweight -> Neutral

Reason

JPMorgan downgraded Hologic (HOLX) to Neutral from Overweight with a $78 price target after the company agreed to be acquired by funds managed by Blackstone (BX) and TPG (TPG) in a transaction valued at up to $79 per share, representing an enterprise value of up to $18.3B.

Raymond James

Andrew Cooper

Outperform -> Market Perform

downgrade

$79

2025-10-21

Reason

Raymond James

Andrew Cooper

Price Target

$79

2025-10-21

downgrade

Outperform -> Market Perform

Reason

Raymond James analyst Andrew Cooper downgraded Hologic (HOLX) to Market Perform from Outperform after the company agreed to be acquired by funds managed by Blackstone (BX) and TPG (TPG) in a transaction valued at up to $79 per share, representing an enterprise value of up to $18.3B.

William Blair

Andrew Brackmann

Outperform -> Market Perform

downgrade

$79

2025-10-21

Reason

William Blair

Andrew Brackmann

Price Target

$79

2025-10-21

downgrade

Outperform -> Market Perform

Reason

William Blair analyst Andrew Brackmann downgraded Hologic (HOLX) to Market Perform from Outperform after the company agreed to be acquired by funds managed by Blackstone (BX) and TPG (TPG) in a transaction valued at up to $79 per share, representing an enterprise value of up to $18.3B.

BofA

downgrade

2025-10-20

Reason

BofA

Price Target

2025-10-20

downgrade

Reason

BofA moved to No Rating on Hologic (HOLX) following a news report that said Blackstone (BX) and TPG (TPG) are in the process of lining up $9B-$10B worth of debt financing as part of a process to acquire the company. This is the third news report in the last few months indicating interest, notes the firm, which says the reports lead it to believe a take-private deal is increasingly likely and that shares are no longer trading on fundamentals.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Hologic Inc (HOLX.O) is 16.25, compared to its 5-year average forward P/E of 17.53. For a more detailed relative valuation and DCF analysis to assess Hologic Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

17.53

Current PE

16.25

Overvalued PE

21.19

Undervalued PE

13.87

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

12.93

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

15.25

Undervalued EV/EBITDA

10.62

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

4.67

Current PS

74.22

Overvalued PS

9.93

Undervalued PS

-0.60

Financials

Annual

Quarterly

FY2025Q4

YoY :

+6.22%

1.05B

Total Revenue

FY2025Q4

YoY :

+7.07%

253.00M

Operating Profit

FY2025Q4

YoY :

+4.87%

187.30M

Net Income after Tax

FY2025Q4

YoY :

+9.21%

0.83

EPS - Diluted

FY2025Q4

YoY :

-3.56%

324.70M

Free Cash Flow

FY2025Q4

YoY :

-1.11%

55.33

Gross Profit Margin - %

FY2025Q4

YoY :

-22.35%

22.06

FCF Margin - %

FY2025Q4

YoY :

-1.27%

17.85

Net Margin - %

FY2025Q4

YoY :

-25.00%

8.70

ROIC

Trading Trends

Insider
Hedge Fund
Congress Trading

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

9.8M

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

1.9M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

300.8K

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 4616.24% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

20.7K

Volume

0-12

Months

408.8K

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

2.9M

Volume

Months

0-12

62.3K

Volume

Months

Congress Trading

Congress areSelling! The selling amount has increased368.75%over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

75.0K

USD

6-9

Months

16.0K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

9.8M

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

1.9M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

300.8K

USD

Months

0-12

0.0

USD

Months

HOLX News & Events

Events Timeline

2025-11-03 (ET)

2025-11-03

16:03:00

Hologic announces Q4 adjusted EPS of $1.13, surpassing consensus estimate of $1.10

2025-11-03

14:28:13

Prominent Companies Set to Report After Market Close

2025-10-21 (ET)

2025-10-21

08:51:49

Blackstone to Acquire Hologic for $18.3 Billion

News

7.0

05:54 AMGlobenewswire

BRODSKY & SMITH INVESTOR ALERT: Updates on Investigations Involving Golden Entertainment, Inc. (Nasdaq - GDEN), Brighthouse Financial, Inc. (Nasdaq - BHF), Forge Global Holdings, Inc. (NYSE - FRGE), and Hologic, Inc. (Nasdaq – HOLX)